Enorama Pharma AB (publ) Profit Margin

Enorama Pharma AB (publ) (ERMA.ST) currently reports a profit margin of -4121.55% as of June 2026. That compares with -622.36% in the prior-year period — down 562.2% year over year. That is below the sector sector average of 13.23%. Use the charts on this page to explore Enorama Pharma AB (publ)'s profit margin history and peer comparisons.

Enorama Pharma AB (publ)'s profit margin decreased from -622.36% to -4121.55% — a 562.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Enorama Pharma AB (publ)'s profit margin of -4121.55% is lower than the its sector sector average of 13.23%. That is roughly 31262.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Enorama Pharma AB (publ)'s current -4121.55% should be judged against industry norms (sector average: 13.23%) and against ERMA.ST's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -4121.55%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.23%. From there, open related valuation or income-statement pages for Enorama Pharma AB (publ), and consider following ERMA.ST for alerts when major investors trade the stock.